Investors

Biostage is an evolving leader in regenerative medicine, patient-specific stem cell therapy, and tissue engineering. The company develops customized bioengineered organ implants designed to restore organ function of the esophagus, trachea and bronchus damaged by disease or trauma.

Biostage has built a dedicated internal team of materials scientists, engineers and biologists who are working with our external collaborators to bring our products to the patients who need them as quickly as possible.

Stock Information
OTCQBBSTG
Press Releases
May 14, 2019
Biostage Reports First Quarter 2019 Financial Results

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...

May 8, 2019
Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...

Mar 28, 2019
Biostage Reports 2018 Financial Results

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...

More >

Contact Us

Biostage, Inc.
84 October Hill Road
Suite 11
Holliston, Massachusetts 01746
United States

Phone: 774-233-7300
Toll Free: 855-209-3104
Fax: 774-233-7302

Investor Presentation

  Download PDF

Fact Sheet